Immune idiosyncratic DILI by ICIs: specifics of published cases based on evidence as evaluated for causality by RUCAM
- 1Department of Internal Medicine II, Division of Gastroenterology and Hepatology, Klinikum Hanau, Academic Teaching Hospital of the Medical Faculty, Goethe University Frankfurt/Main
- 2Pharmacovigilance Consultancy
Abstract
The diagnosis of immune idiosyncratic drug-induced liver injury (iDILI) by immune checkpoint inhibitors (ICIs) is blurred by the heterogeneity of causality attribution in cancer patients; this requires information gaps to be filled through the collection of cases evaluated for causality by the Roussel Uclaf Causality Assessment Method (RUCAM). RUCAM was used in 8/11 reports (73%), providing a rather homogeneous study cohort for the following manifestation specifics: (1) consensus among the eight RUCAM-based reports that iDILI by ICIs has an immune basis; (2) age of most patients > 60 years; (3) male gender dominated by a factor ranging from 1.5- to 4.0-fold; (4) clinical manifestations at admission included weakness, vomiting, epigastric pain, and itching but not necessarily jaundice; (5) serum activities of ALT up to 3,111 U/L, with ALP up to 2,459 U/L and total bilirubin up to 300 μmol/L; (6) RUCAM-based ratio (R) revealing a pattern of hepatocellular liver injury (42%), cholestatic (39%), and mixed liver injury (19%); (7) therapeutic options require a case-by-case decision, as the natural course is variable among the cancer patients; (8) although treatment with steroids and/or ursodeoxycholic acid was commonly effective, a therapy decision has to consider whether the use of the implicated ICI should be stopped or continued; (9) prognosis depends largely on disease severity; (10) among the cancer patients with DILI by ICIs, 22% died during follow-up, mostly after progress of underlying disease. In brief, RUCAM use allows for the correct description of clinical manifestations, but more diagnostic efforts are needed for iDILI by ICIs if associated with the novel autoimmune pancreatitis type AIP-3, reflecting pancreatic involvement with possible secondary sclerosing cholangitis.
Related
- Terminalia buceras (Syn. Bucida buceras) and Retinal Oxidative Stress: A Critical Review of Published Evidence and Its Relevance to Dry Age-Related Macular Degeneration
- Proof-of-concept phase II study protocol to evaluate the efficacy and safety of prednisone in the treatment of idiosyncratic hepatotoxicity and its mechanistic pathways through an integrative analysis: the DILICORT clinical trial
- Metformin use and the risk of incident breast cancer: a systematic review and meta-analysis accounting for time-related biases, and why imeglimin cannot yet be evaluated
- Virtual Reality Simulation in Colonoscopy Training: A Systematic Review and Meta-analysis of Studies Published from 2019 to 2024
- Factors influencing baseline electrocardiographic parameters in rats: A systematic review of experimental studies published from 1960 to the present
BibTeX
@article{teschke2026immune,
title = {{Immune idiosyncratic DILI by ICIs: specifics of published cases based on evidence as evaluated for causality by RUCAM}},
author = {Rolf Teschke and Gaby Danan},
journal = {Frontiers in Pharmacology},
year = {2026},
month = nov,
doi = {10.3389/fphar.2026.1974945},
url = {https://www.frontiersin.org/articles/10.3389/fphar.2026.1974945/full},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Immune idiosyncratic DILI by ICIs: specifics of published cases based on evidence as evaluated for causality by RUCAM
AU - Rolf Teschke
AU - Gaby Danan
PY - 2026
DA - 2026/11/05
JO - Frontiers in Pharmacology
DO - 10.3389/fphar.2026.1974945
UR - https://www.frontiersin.org/articles/10.3389/fphar.2026.1974945/full
AB - The diagnosis of immune idiosyncratic drug-induced liver injury (iDILI) by immune checkpoint inhibitors (ICIs) is blurred by the heterogeneity of causality attribution in cancer patients; this requires information gaps to be filled through the collection of cases evaluated for causality by the Roussel Uclaf Causality Assessment Method (RUCAM). RUCAM was used in 8/11 reports (73%), providing a rather homogeneous study cohort for the following manifestation specifics: (1) consensus among the eight RUCAM-based reports that iDILI by ICIs has an immune basis; (2) age of most patients > 60 years; (3) male gender dominated by a factor ranging from 1.5- to 4.0-fold; (4) clinical manifestations at admission included weakness, vomiting, epigastric pain, and itching but not necessarily jaundice; (5) serum activities of ALT up to 3,111 U/L, with ALP up to 2,459 U/L and total bilirubin up to 300 μmol/L; (6) RUCAM-based ratio (R) revealing a pattern of hepatocellular liver injury (42%), cholestatic (39%), and mixed liver injury (19%); (7) therapeutic options require a case-by-case decision, as the natural course is variable among the cancer patients; (8) although treatment with steroids and/or ursodeoxycholic acid was commonly effective, a therapy decision has to consider whether the use of the implicated ICI should be stopped or continued; (9) prognosis depends largely on disease severity; (10) among the cancer patients with DILI by ICIs, 22% died during follow-up, mostly after progress of underlying disease. In brief, RUCAM use allows for the correct description of clinical manifestations, but more diagnostic efforts are needed for iDILI by ICIs if associated with the novel autoimmune pancreatitis type AIP-3, reflecting pancreatic involvement with possible secondary sclerosing cholangitis.
SN - 1663-9812
ER -